Natural killer cell biology: An update and future directions

被引:311
作者
Campbell, Kerry S. [1 ]
Hasegawa, Jun [1 ]
机构
[1] Fox Chase Canc Ctr, Res Inst, Cell Dev & Host Def Program, Philadelphia, PA 19111 USA
基金
美国国家卫生研究院;
关键词
Natural killer cell; killer cell immunoglobulin-like receptors; innate immunity; immune memory; antibody-dependent cellular cytotoxicity; cancer; viral infection; hematopoietic stem cell transplantation; immunomodulatory drugs; IFN-gamma; MHC CLASS-I; INNATE LYMPHOID-CELLS; NK-CELLS; INHIBITORY RECEPTORS; SELF-MHC; MOLECULAR-MECHANISMS; BORTEZOMIB TREATMENT; PERIPHERAL-BLOOD; PHASE-1; TRIAL; KIR ANTIBODY;
D O I
10.1016/j.jaci.2013.07.006
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Natural killer (NK) cells constitute a minor subset of normal lymphocytes that initiate innate immune responses toward tumor and virus-infected cells. They can mediate spontaneous cytotoxicity toward these abnormal cells and rapidly secrete numerous cytokines and chemokines to promote subsequent adaptive immune responses. Significant progress has been made in the past 2 decades to improve our understanding of NK cell biology. Here we review recent discoveries, including a better comprehension of the "education'' of NK cells to achieve functional competence during their maturation and the discovery of "memory'' responses by NK cells, suggesting that they might also contribute to adaptive immunity. The improved understanding of NK cell biology has forged greater awareness that these cells play integral early roles in immune responses. In addition, several promising clinical therapies have been used to exploit NK cell functions in treating patients with cancer. As our molecular understanding improves, these and future immunotherapies should continue to provide promising strategies to exploit the unique functions of NK cells to treat cancer, infections, and other pathologic conditions.
引用
收藏
页码:536 / 544
页数:9
相关论文
共 116 条
[1]   2B4 (CD244) Signaling by Recombinant Antigen-specific Chimeric Receptors Costimulates Natural Killer Cell Activation to Leukemia and Neuroblastoma Cells [J].
Altvater, Bianca ;
Landmeier, Silke ;
Pscherer, Sibylle ;
Temme, Jaane ;
Schweer, Katharina ;
Kailayangiri, Sareetha ;
Campana, Dario ;
Juergens, Heribert ;
Pule, Martin ;
Rossig, Claudia .
CLINICAL CANCER RESEARCH, 2009, 15 (15) :4857-4866
[2]   The ever-expanding Ly49 gene family:: repertoire and signaling [J].
Anderson, SK ;
Ortaldo, JR ;
McVicar, DW .
IMMUNOLOGICAL REVIEWS, 2001, 181 :79-89
[3]   Human NK cell education by inhibitory receptors for MHC class I [J].
Anfossi, Nicolas ;
Andre, Pascale ;
Guia, Sophie ;
Falk, Christine S. ;
Roetynck, Sophie ;
Stewart, C. Andrew ;
Breso, Violette ;
Frassati, Coralie ;
Reviron, Denis ;
Middleton, Derek ;
Romagne, Francois ;
Ugolini, Sophie ;
Vivier, Eric .
IMMUNITY, 2006, 25 (02) :331-342
[4]   Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].
Arai, S. ;
Meagher, R. ;
Swearingen, M. ;
Myint, H. ;
Rich, E. ;
Martinson, J. ;
Klingemann, H. .
CYTOTHERAPY, 2008, 10 (06) :625-632
[5]   Direct and natural killer cell-mediated antitumor effects of low-dose Bortezomib in hepatocellular carcinoma [J].
Armeanu, Sorin ;
Krusch, Matthias ;
Baltz, Katrin M. ;
Weiss, Thomas S. ;
Smirnow, Irina ;
Steinle, Alexander ;
Lauer, Ulrich M. ;
Bitzer, Michael ;
Salih, Helmut R. .
CLINICAL CANCER RESEARCH, 2008, 14 (11) :3520-3528
[6]   Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[7]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[8]   IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Zhang, Shuhong ;
Collins, Shauna M. ;
Liang, Jing ;
Srivastava, Shivani ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Andre, Pascale ;
Romagne, Francois ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Zhang, Jianying ;
Clever, David ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2011, 118 (24) :6387-6391
[9]   The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody [J].
Benson, Don M., Jr. ;
Bakan, Courtney E. ;
Mishra, Anjali ;
Hofmeister, Craig C. ;
Efebera, Yvonne ;
Becknell, Brian ;
Baiocchi, Robert A. ;
Zhang, Jianying ;
Yu, Jianhua ;
Smith, Megan K. ;
Greenfield, Carli N. ;
Porcu, Pierluigi ;
Devine, Steven M. ;
Rotem-Yehudar, Rinat ;
Lozanski, Gerard ;
Byrd, John C. ;
Caligiuri, Michael A. .
BLOOD, 2010, 116 (13) :2286-2294
[10]   NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs [J].
Beziat, Vivien ;
Liu, Lisa L. ;
Malmberg, Jenny-Ann ;
Ivarsson, Martin A. ;
Sohlberg, Ebba ;
Bjorklund, Andreas T. ;
Retiere, Christelle ;
Sverremark-Ekstrom, Eva ;
Traherne, James ;
Ljungman, Per ;
Schaffer, Marie ;
Price, David A. ;
Trowsdale, John ;
Michaelsson, Jakob ;
Ljunggren, Hans-Gustaf ;
Malmberg, Karl-Johan .
BLOOD, 2013, 121 (14) :2678-2688